
Paget's Disease: Diagnosis, Management, and Insights into the Breast (PDB)
Paget's disease of the breast is a rare kind of breast cancer that mostly affects the skin around the nipple. It happens in only a small number of breast cancer cases because it's linked to certain gene changes and other types of breast tumors. Doctors notice it more in women who have stopped having periods (postmenopausal women). Things like what you eat, where you live, and how often you get check-ups can change your chances of having this disease.
Paget's disease of the breast is found more often in countries like the United States and those in Western Europe, compared to places in Asia. This could be because people in those countries have more access to doctors, tests, and information about breast health. Even though this disease is not very common, it's important to pay attention to it because it can be connected to other serious breast tumors. Catching and treating it early helps people have better results and stay healthier in the long run.
Table of Contents:
Paget's disease of the breast is a rare breast cancer that affects the skin of the nipple and sometimes the areola. It is characterized by a rash or eczema like appearance on the nipple and areola which can be accompanied by itching, redness and discharge. It is often associated with an underlying breast cancer which can be invasive or non-invasive (ductal carcinoma in situ, DCIS). Paget's disease of the breast is named after Sir James Paget, a 19th century British doctor who first described the condition.
The pathogenesis of PDB is explained by two theories:
The first theory is the epidermotropic theory which suggests that Paget cells come from an underlying ductal carcinoma in situ (DCIS) or invasive breast carcinoma. These cells retain their malignant properties and contribute to the histopathological findings of Paget's disease. These cancer cells are thought to migrate from an underlying carcinoma through the lactiferous ducts to the nipple epidermis.
The second theory is the in situ transformation theory which suggests that Paget cells arise as a primary intraepidermal malignancy independent of any underlying breast carcinoma. This theory is supported by cases where no underlying breast tumor is found.
Epidermotropic Theory: This is the most widely accepted theory which suggests that malignant ductal cells migrate from an underlying carcinoma through the lactiferous ducts to the epidermis of the nipple. These cells retain their malignant properties and contribute to the histopathological findings of Paget's disease. This theory is supported by the frequent finding of underlying DCIS or invasive carcinoma in patients with PDB. In some cases this underlying carcinoma can be an invasive breast cancer which affects the prognosis and treatment.
In Situ Transformation Theory: This is an alternative theory which suggests that malignant cells arise de novo within the epidermis of the nipple possibly due to local field effects or genetic mutations. Although this theory is less accepted, it highlights the complexity of the disease. Further research is needed to understand the molecular mechanisms.
Characteristic features are large, pale, vacuolated Paget cells in the epidermis often with HER2 overexpression. The strong association with DCIS or invasive carcinoma emphasizes the need for full evaluation. [2] Recent studies have looked at molecular pathways including HER2 signaling and immune evasion mechanisms as potential targets for treatment. For example HER2 targeted therapy like trastuzumab has shown promise in improving outcomes.
Paget's disease of the breast is a rare condition and accounts for about 1-4% of all breast cancer. The exact cause of Paget's disease is not known but it is associated with underlying breast cancer. The risk factors for Paget's disease are similar to breast cancer:
Knowing these risk factors is important for early detection and prevention. Regular screenings and genetic counseling can help identify those at higher risk and can be managed proactively. [4]
PDB usually presents with changes in the nipple-areola complex:
Unilateral symptoms are common but bilateral symptoms are rare and should prompt consideration of other diagnoses. Symptom progression varies; early cases may present with subtle scaling and advanced cases may have ulceration and nipple destruction. Recognizing these stages is important for timely interventions. Case studies show that early detection of these subtle signs can improve prognosis.
Diagnosis of PDB is a combination of clinical evaluation, imaging and histopathological assessment. If an underlying cancer is suspected, a sentinel lymph node biopsy may be done to assess the spread of cancer to the axillary lymph nodes. [5]
A comparison of imaging modalities shows that MRI is more sensitive than mammography and ultrasound especially in younger patients or those with dense breasts. However, the cost and false positive results should be considered. Advanced techniques like diffusion-weighted imaging (DWI) and contrast-enhanced mammography are emerging as promising tools to improve diagnostic accuracy.
Immunohistochemistry: HER2 is overexpressed in 80-100% of cases, ER and PR status varies depending on the underlying cancer. Advances in molecular diagnostics including next-generation sequencing is helping us understand the genetic basis of PDB. For example, TP53 and PIK3CA mutations have been linked to disease progression and potential targets for therapy.
Treatment of PDB depends on the extent of disease and presence of underlying cancer. Treatment options are surgery, radiation and systemic therapy.
Radiation Therapy: Reduces local recurrence, especially after BCS. Whole breast radiation therapy is usually recommended after BCS to make sure any remaining cancer cells are killed and reduce the risk of recurrence.
Oncoplastic surgery has improved the cosmetic outcome for BCS patients. Nipple-sparing mastectomy is also becoming popular, balancing oncological safety and aesthetic preservation. 3D imaging and intraoperative margin assessment has further improved surgical precision.
Emerging therapies like antibody-drug conjugates (e.g. trastuzumab deruxtecan) and immune checkpoint inhibitors are being studied in clinical trials and may add to the treatment options for PDB. Combination therapy targeting both HER2 and PD-1/PD-L1 are showing promising results in early phase trials and may be the future of personalized medicine.
Prognosis of Paget's disease of the breast depends on the underlying cancer and stage of the disease. If the underlying cancer is non-invasive (DCIS), prognosis is good, 5 year survival is over 90%. If the underlying cancer is invasive, prognosis is poor, 5 year survival is 50-60%. Prognosis is poorer if the cancer has spread to the nodes or other parts of the body.
Early detection and comprehensive treatment is key to better outcomes. Advances in imaging and targeted therapy has improved the management of Paget's disease and hope for better survival and quality of life.
In peripartum women presenting with nipple-areola complex changes, PDB should be included in the differential diagnosis. PDB is often associated with tumors in the same breast tissue so it is important to evaluate the same breast for any underlying tumors. Diagnostic delays are common because PDB looks like benign conditions.
Multidisciplinary management is important to balance maternal and fetal well being while ensuring prompt treatment [2]. Case reports have shown the challenges of managing PDB during pregnancy and the importance of individualized care plan. Imaging modalities like ultrasound which is non-ionizing radiation is preferred during pregnancy.
Modern Treatment TrendsBreast conserving approach is the trend now with improvements in imaging, surgery and adjuvant therapy. Personalized treatment plan based on tumor biology and patient preference has resulted to better functional and cosmetic outcome. AI is also being integrated in imaging and pathology to aid in earlier detection and more accurate diagnosis of PDB.
Patient education and awareness is key in the diagnosis and treatment of Paget's disease of the breast. Women should be aware of the signs and symptoms of Paget's disease, a rash or eczema like appearance on the nipple and areola, itching, redness and discharge. Women should also be aware of their risk for breast cancer and take steps to reduce their risk, get regular mammograms and do breast self exam.
Educational campaigns and resources can help women to seek medical attention if they notice any changes in their breast tissue. Early intervention can make a big difference in prognosis and treatment outcome.
Multidisciplinary approach is important in the diagnosis and treatment of Paget's disease of the breast. A team of healthcare professionals including breast surgeon, medical oncologist, radiation oncologist and pathologist should work together to develop a treatment plan that is individualized to the patient. Treatment may include surgery, radiation therapy, chemotherapy and hormone therapy depending on the underlying cancer and stage of the disease.
Team work among specialists ensures comprehensive care of all aspects of the disease. This team based approach not only improves clinical outcome but also the overall well being of the patient and provide holistic treatment experience.
Paget's disease of the breast is a rare but significant malignancy that requires high index of suspicion for early diagnosis. Mammary Paget disease which involves the nipple-areola complex requires thorough understanding of its clinical presentation and underlying pathology.
Advances in imaging, histopathology and systemic therapy has improved diagnostic accuracy and treatment outcome. Breast conserving surgery when possible is a trend towards less invasive management which is patient centered.
Future research should focus on the molecular mechanism of PDB and identification of new therapeutic targets to further improve outcome. Development of AI driven diagnostic tool and precision therapy will be the game changer in PDB management in the coming years.
[1] Hudson-Phillips, S., Cox, K., Patel, P., & Al Sarakbi, W. (2023). Paget's disease of the breast: diagnosis and management. British journal of hospital medicine (London, England : 2005), 84(1), 1–8. https://doi.org/10.12968/hmed.2022.0439
[2] Gilmore, R., Prasath, V., & Habibi, M. (2020). Paget Disease of the Breast in Pregnancy and Lactation. Advances in experimental medicine and biology, 1252, 133–136. https://doi.org/10.1007/978-3-030-41596-9_18
[3] Karakas C. (2011). Paget's disease of the breast. Journal of carcinogenesis, 10, 31. https://doi.org/10.4103/1477-3163.90676
[4] Dalton, J. C., & Plichta, J. K. (2024). Paget's disease of the breast: Insights from imaging to guide surgical management. American journal of surgery, 231, 16–17. https://doi.org/10.1016/j.amjsurg.2024.03.013
[5] Sakorafas, G. H., Blanchard, K., Sarr, M. G., & Farley, D. R. (2001). Paget's disease of the breast. Cancer treatment reviews, 27(1), 9–18. https://doi.org/10.1053/ctrv.2000.0203

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business of Fashion
an hour ago
- Business of Fashion
L'Oréal to Acquire British Skincare Brand Medik8
L'Oréal has acquired a majority stake in British skincare brand Medik8, the companies announced Monday. The brand will be managed under the beauty giant's Luxe division, sitting alongside premium lines like Aesop and Kiehl's. The terms of the transaction were not disclosed, though a recent report in the Financial Times said the brand was valued at roughly $1 billion. Medik8, which was founded in 2009 by Elliot Isaacs, sells science-backed serums that are designed to preserve and restore skin, including its popular Liquid Peptides ($66) and Crystal Retinal ($85) ranges. It has a production and research facility in Buckinghamshire, England, where it manufactures its products. In 2021, Medik8 was acquired by private equity firm Inflexion. Sales reached $70 million to $80 million in 2024, following a push into the US market. Science-backed skincare has been a boon for L'Oréal, which also owns other 'dermocosmetics' brands like the mass lines Cerave and La Roche Posay, as well prestige names like Skinceuticals and Skinbetter Science. 'We share a strong belief in Medik8's global potential,' said Cyril Chapuy, president of L'Oréal Luxe, in a statement. Sign up to The Business of Beauty newsletter, your complimentary, must-read source for the day's most important beauty and wellness news and analysis. Beauty's Top M&A Targets for 2025 After a slow year for acquisitions, brands and investors alike are hoping that 2025 will yield bigger exits. But with most strategic buyers like L'Oréal operating with an even narrower lens, only a select few firms will make it across the finish line.
Yahoo
13 hours ago
- Yahoo
Time to face the harsh realities of spending orthodoxy
Labour came to power fatuously parroting the word 'change' and yet has shown itself to be the same old tax and spending party it has always been. What it meant was a change of party in office not a change of direction. Not only have taxes gone up but so-called protected spending is set to rise despite record debt levels. Yet if ever a public policy has been tested to destruction surely it is the notion that the NHS will improve if only more money is thrown at it. Even Sir Keir Starmer and Wes Streeting, the Health Secretary, are on record as saying that higher health spending is not the answer to the endemic flaws in the health service and yet another £30 billion is to be announced for the next three years on top of the £22 billion handed over after last year's general election, much of which went on pay and showed nothing in the way of productivity improvement. No mainstream politician is prepared to acknowledge that the problem with the NHS is the fact it is a nationalised industry with all the inherent inefficiencies associated with such. Most other advanced economies in Europe and elsewhere have social insurance systems which work better. But the insistence in Britain of cleaving to the 1948 'founding principle' that treatment should be free at the point of delivery has become a quasi-religious doctrine that few dare challenge. Only Nigel Farage has questioned the wisdom of continuing with a system that patently fails to achieve what others manage to do but has been noticeably quiet on the subject recently because Labour will exploit it mercilessly to see off the Reform people that they will have to pay for something they have always had for free is even more difficult when political parties are prepared to see the health system get worse rather than reform it. The same is true of welfare. Taking benefits from people, even when they are payments introduced just a few years ago like the winter fuel allowance, is hard if the reasons are not explained and the issue is 'weaponised' by opponents. Yet unless the welfare budget is brought under control it will bankrupt the country. If change is to mean anything then we need politicians finally to understand the extent of the country's difficulties and make decisions accordingly. Will we see that from the Chancellor on Wednesday? Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Yahoo
3 days ago
- Yahoo
Churchill documents reveal D-Day landings boosted by import of ‘wonder drug' from America
Newly unearthed documents have revealed that the D-Day landings received a boost from the import of a "wonder drug" from America. Despite its discovery in London in 1928 by Sir Alexander Fleming, large-scale production of the antibiotic penicillin had struggled to take hold in Britain. Attempts to produce substantial quantities of medicine from the bacteria-killing mould had not been achieved by the start of the Second World War. Then prime minister Sir Winston Churchill became increasingly frustrated that Britain had not been able to produce enough penicillin in the preparations for the Normandy landings in 1944. Official papers released by the National Archive – containing handwritten notes by Sir Winston – highlight efforts to boost quantities of the antibiotic, with Britain eventually forced to import it from America. The documents were released ahead of the 81st anniversary of D-Day, the Allied invasion of Normandy on June 6, 1944. In one report on February 19, after the issue had been raised in the House of Commons, Sir Winston scrawled in red ink on a Ministry of Supply report noting the Americans were producing greater quantities: 'I am sorry we can't produce more.' On another paper, he complained: 'Your report on penicillin showing that we are only to get about one tenth of the expected output this year, is very disappointing.' Elsewhere in the same file he instructs: 'Let me have proposals for a more abundant supply from Great Britain.' With preparations for D-Day ramped up, efforts to deliver enough American-made penicillin for frontline military personnel soon became a matter of urgency. Decisions needed to be made on the quantities of antibiotic imported, how much to administer to individual patients, and how to get medical staff trained in time. Most British doctors did not know how to issue penicillin – until this point, doctors had nothing available to treat infections like pneumonia and many people died of blood poisoning after minor injuries because no drug existed that could cure them. Early in January 1944, Prof FR Fraser, the Ministry of Health's adviser on the organisation of wartime hospitals, wrote that 50,000-100,000 wounded could be expected from the Second Front. He proposed the Emergency Medical Services might need as many as five billion units of penicillin per month for this. Further documents show discussions on whether the antibiotic should be supplied as calcium or sodium salts, or in tablet form. Ultimately, it was agreed powdered calcium salts would be issued for superficial wounds and sodium salts for use in deep wounds. On May 24 1944, less than a fortnight before D-Day, Prof Fraser reported: 'Sufficient supplies of penicillin are now available for the treatment of battle casualties in EMS hospitals, but not for ordinary civilian patients.' Plans were made for casualties from the frontline in France to be brought back to coastal hospitals in Britain for treatment. A week before D-Day, on May 30 1944, hospitals were instructed to treat battlefield patients en route: 'In an endeavour to prevent the development of gas gangrene and sepsis in wounds the War Office have arranged for the treatment of selected cases by penicillin to be commenced as soon after injury as possible.' Injections of penicillin were to be given to them at intervals of not more than five hours and patients would be wearing a yellow label with the letters 'PEN'. The time and size of penicillin doses should be written on it, they were told. Dr Jessamy Carlson, modern records specialist at the National Archives, said: 'File MH 76/184 gives a glimpse into the extraordinary levels of preparation undertaken in advance of the D-Day landings. 'Only six weeks before, penicillin is just reaching our shores in quantities which will allow it to play a major role in improving the outcomes for service personnel wounded in action.' As Allied forces made inroads into Europe, restrictions on the use of penicillin for civilians began to relax, but only in special cases. In July 1944, Ronald Christie, professor of medicine, wrote to Prof Fraser to tell him: 'The War Office approves of American penicillin being used for medical conditions in service patients and for air raid casualties among civilians.' On the home front, demand for the new 'wonder' drug began to increase, according the National Archives. It was decided that penicillin for civilians should only be supplied to larger hospitals where the staff had been properly trained to administer it. Only in 1946 did it become fully available for the general public.